Table 1.
Patient Number | Hydroxyurea | ED Utilization | Placebo Proportion Prior to Randomization | Hydroxyurea Imbalance | Moderate ED Imbalance | High ED Imbalance | Overall Weighted Imbalance | Randomization Vector (Probability of placebo) | Assignment |
---|---|---|---|---|---|---|---|---|---|
1 | Taking | Moderate | 0* | 0 | 0 | 0 | 0 | 0.33* | Treatment |
2 | Not Taking | High | 0* | −1.00 | −1.00 | 1.00 | −1.00 | 0.33* | Placebo |
3 | Taking | Low | 0.50 | −0.50 | −1.00 | 0.50 | −0.75 | 0.19 | Placebo |
4 | Taking | Moderate | 0.67 | −0.50 | −1.00 | 0.50 | −0.75 | 0.11 | Treatment |
5 | Taking | Moderate | 0.50 | −0.33 | −0.67 | 0.33 | −0.50 | 0.19 | Placebo |
6 | Taking | Moderate | 0.60 | −0.33 | −0.67 | 0.33 | −0.50 | 0.14 | Treatment |
7 | Not Taking | Moderate | 0.50 | −0.08 | −0.67 | 0.33 | −0.25 | 0.19 | Treatment |
8 | Not Taking | High | 0.43 | 0.07 | −0.47 | 0.13 | −0.10 | >0.01 | Treatment |
9 | Taking | High | 0.38 | 0 | −0.33 | 0 | −0.17 | 0.16 | Treatment |
10 | Not Taking | Moderate | 0.33 | 0.10 | −0.38 | 0.05 | −0.07 | 0.51 | Treatment |
11 | Not Taking | Moderate | 0.30 | 0.17 | −0.42 | 0.08 | 0 | 0.78 | Treatment |
12 | Not Taking | Moderate | 0.27 | 0 | −0.25 | 0 | −0.13 | 0.91 | Placebo |
13 | Taking | Low | 0.33 | −0.06 | −0.17 | 0.03 | −0.13 | >0.01 | Treatment |
14 | Taking | High | 0.31 | 0.04 | −0.27 | 0.18 | 0 | 0.51 | Placebo |
15 | Not Taking | Moderate | 0.36 | 0.10 | −0.30 | 0.20 | 0.05 | 0.51 | Treatment |
16 | Not Taking | Low | 0.33 | 0.15 | −0.24 | 0.22 | 0.14 | 0.16 | Treatment |
17 | Taking | Moderate | 0.31 | 0.21 | −0.14 | 0.15 | 0.22 | 0.51 | Placebo |
18 | Not Taking | Low | 0.35 | 0.12 | −0.21 | 0.10 | 0.06 | 0.51 | Placebo |
19 | Taking | Moderate | 0.39 | 0.07 | −0.24 | 0.12 | 0.01 | 0.01 | Treatment |
20 | Taking | Moderate | 0.37 | 0.03 | −0.26 | 0.13 | −0.03 | 0.33 | Treatment |
21 | Taking | High | 0.35 | 0 | −0.21 | 0.07 | −0.07 | 0.01 | Treatment |
22 | Taking | Low | 0.33 | −0.03 | −0.17 | 0.09 | −0.07 | 0.33 | Treatment |
23 | Taking | Low | 0.32 | −0.05 | −0.13 | 0.10 | −0.07 | 0.33 | Treatment |
24 | Not Taking | Low | 0.30 | −0.02 | −0.10 | 0.11 | −0.01 | 0.01 | Treatment |
25 | Taking | Moderate | 0.29 | 0.04 | −0.03 | 0.07 | 0.06 | 0.33 | Placebo |
26 | Taking | Moderate | 0.32 | 0.01 | −0.06 | 0.08 | 0.03 | 0.01 | Treatment |
27 | Taking | Moderate | 0.31 | 0.06 | 0 | 0.06 | 0.08 | 0.33 | Placebo |
28 | Taking | Moderate | 0.33 | 0.04 | −0.02 | 0.06 | 0.06 | >0.01 | Treatment |
29 | Not Taking | Moderate | 0.32 | −0.03 | 0.02 | 0.04 | 0 | 0.78 | Placebo |
30 | Not Taking | High | 0.34 | 0 | 0.05 | 0 | 0.03 | 0.33 | Treatment |
31 | Not Taking | High | 0.33 | −0.05 | 0 | 0.07 | −0.02 | 0.33 | Placebo |
32 | Taking | Low | 0.35 | −0.07 | 0.02 | 0.08 | −0.02 | 0.51 | Treatment |
33 | Taking | Low | 0.34 | −0.04 | −0.02 | 0.06 | −0.02 | 0.78 | Placebo |
34 | Taking | Moderate | 0.36 | −0.05 | −0.05 | 0.07 | −0.04 | 0.33 | Treatment |
35 | Taking | Low | 0.35 | −0.07 | −0.02 | 0.08 | −0.04 | 0.33 | Treatment |
36 | Not Taking | High | 0.34 | −0.04 | 0 | 0.04 | −0.02 | >0.01 | Treatment |
37 | Not Taking | Moderate | 0.33 | −0.09 | 0.04 | 0.02 | −0.06 | 0.16 | Placebo |
38 | Not Taking | Moderate | 0.35 | −0.06 | 0.02 | 0.03 | −0.04 | >0.01 | Treatment |
39 | Taking | Moderate | 0.34 | −0.08 | 0 | 0.04 | −0.06 | 0.16 | Treatment |
40 | Taking | Low | 0.33 | −0.09 | 0.02 | 0.05 | −0.06 | 0.51 | Treatment |
41 | Taking | High | 0.33 | −0.10 | 0.04 | 0.02 | −0.08 | 0.16 | Treatment |
42 | Taking | Low | 0.32 | −0.12 | 0.06 | 0.02 | −0.08 | 0.78 | Treatment |
43 | Taking | Low | 0.31 | −0.08 | 0.02 | 0.01 | −0.07 | 0.91 | Placebo |
44 | Taking | Low | 0.33 | −0.06 | −0.02 | −0.01 | −0.07 | 0.51 | Placebo |
45 | Taking | High | 0.34 | −0.07 | 0 | −0.03 | −0.08 | 0.51 | Treatment |
The progress and treatment allocation decisions of the single example trial. Weighted overall imbalance is the sum of the hydroxyurea imbalance and one half times the sum of the moderate and high ED imbalances.
The first two patients are enrolled with a 1/3 probability of placebo.